ORLANDO, FLORIDA—Men over 75 were safely and effectively treated for their metastatic castration-resistant prostate cancer with the androgen receptor inhibitor enzalutamide in the Phase III AFFIRM stu
ORLANDO, FLORIDA—Men over 75 were safely and effectively treated for their metastatic castration-resistant prostate cancer with the androgen receptor inhibitor enzalutamide in the Phase III AFFIRM study reported at the 2013 Genitourinary Cancers Symposium. Professor Cora Sternberg Chief of Medical Oncology at the San Camillo & Forlanini Hospitals in Rome gave Peter Goodwin more details about why this new generation hormonal therapy is appropriate and how effective it has proved to be in the AFFIRM study in general and among over 75s in particular.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/130310CoraSternbergAJOPODCASTLoRes.mp3]